Company intelligence / Profile preview

Nodenza Venture Partners

New York, New York, United Statesnodenza.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Nodenza Venture Partners was launched in 2024 as a New York-based venture capital firm focused on investing globally in early-stage and pre-commercial biotech and medtech companies. The team consists of experienced life science entrepreneurs with deep expertise across drug development and commercialization. Their bi-modal strategy targets both new treatment modalities advancing from IND through Phase 2 as well as later-stage/pre-commercial opportunities transitioning toward market launch. They provide both financial backing and operational support to their portfolio companies.

Modalities: Small moleculeBiologicAntibodyGene therapyCell therapy
Industry: Investors

Drug pipeline

1 asset

TRL1068

Phase 2

Indications: Prosthetic joint infection, Infective endocarditis

Beyond the preview

Go deeper on Nodenza Venture Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nodenza Venture Partners.

Explore the full profile